Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
I-MAB (IMAB)
NASDAQ:IMAB
Holding IMAB?
Track your performance easily
IMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.90 - $2.54
Previous Close$0.98
Volume339.84K
Average Volume (3M)378.23K
Market Cap
$73.40M
Enterprise Value-$3.26B
Total Cash (Recent Filing)$3.34B
Total Debt (Recent Filing)$10.87M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Mar 26, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding80,701,592
10 Day Avg. Volume306,419
30 Day Avg. Volume378,230
Standard Deviation0.21
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.05
Price to Sales (P/S)19.53
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.11
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside734.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
I-MAB News
PremiumCompany Announcements
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies
PremiumCompany Announcements
I-Mab’s Promising Q3 Results and Strategic Moves
PremiumCompany Announcements
I-Mab Appoints New CEO to Drive Cancer Therapy Goals
PremiumCompany Announcements
I-Mab Biopharma’s Strategic US Transition and Pipeline Focus
PremiumCompany Announcements
I-MAB Appoints New Board Member and Audit CommitteeOwnership Overview
5.60%
Insiders
0.03% Mutual Funds
14.15% Other Institutional Investors
80.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMAB FAQ
What was I-MAB’s price range in the past 12 months?
I-MAB lowest stock price was $0.90 and its highest was $2.54 in the past 12 months.
What is I-MAB’s market cap?
Currently, no data Available
When is I-MAB’s upcoming earnings report date?
I-MAB’s upcoming earnings report date is Mar 26, 2025 which is in 124 days.
How were I-MAB’s earnings last quarter?
I-MAB released its earnings results on Nov 14, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.04.
Is I-MAB overvalued?
According to Wall Street analysts I-MAB’s price is currently Undervalued.
Does I-MAB pay dividends?
I-MAB does not currently pay dividends.
What is I-MAB’s EPS estimate?
I-MAB’s EPS estimate is -$0.06.
How many shares outstanding does I-MAB have?
I-MAB has 80,882,910 shares outstanding.
What happened to I-MAB’s price movement after its last earnings report?
I-MAB reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 2.885%.
Which hedge fund is a major shareholder of I-MAB?
Among the largest hedge funds holding I-MAB’s share is Caxton Associates LP. It holds I-MAB’s shares valued at N/A.
---
I-MAB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (734.20% Upside)
$8.00 (734.20% Upside)
Blogger Sentiment
Bullish
IMAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 26.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.57%
12-Months-Change
Fundamentals
Return on Equity
-39.60%
Trailing 12-Months
Asset Growth
-47.49%
Trailing 12-Months
Company Description
I-MAB
I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.
---
IMAB Earnings Call
Q2 2024
0:00 / 0:00
---
IMAB Stock 12 Month Forecast
Average Price Target
$8.00
▲(734.20% Upside)
Technical Analysis
Best Analysts Covering IMAB
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-57.81%
reiterated a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.81% per trade.
---